3D Systems Advances Regenerative Medical Solutions for First-of-its-Kind Peripheral Nerve Repair | Collaboration with French MedTech company, TISSIUM, has resulted in FDA approval for unique 3D-printed polymeric solution for repair of peripheral nerve damage3D Systems' bioprinting system enabled... ► Artikel lesen |
3D Systems Announces Significant Strengthening of Balance Sheet | Transactions permanently retire approximately $88 million of debt, 41% of prior balance, at a meaningful discount to parRefinancing extends maturity with issuance of $92 million Convertible Senior... ► Artikel lesen |
3D Systems Reports First Quarter 2025 Financial Results | ROCK HILL, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the first quarter ended March 31, 2025. Revenue of $95 million as growth... ► Artikel lesen |
UltiMaker Unveils the UltiMaker S8, Engineered for Enhanced Productivity and Precision | The UltiMaker S8 delivers up to 4x more productivity and improved part quality, without sacrificing security, reliability or ease of use.
Combined with new materials in the UltiMaker... ► Artikel lesen |
Stratasys Announces Unaudited Preliminary Approximate Fourth Quarter 2024 Financial Results | MINNEAPOLIS & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (Nasdaq: SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced unaudited preliminary approximate... ► Artikel lesen |
Stratasys Launches TrueDent in Europe, Bringing the Benefits of Monolithic Digital Dentures to Dental Labs, Dentists, and Patients | TrueDent-D resin is now available in major European markets that require CE marking, with strong customer interest already building Stratasys (NASDAQ: SSYS) has declared that its TrueDent-D resin... ► Artikel lesen |
VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen |
Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen |
Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen |